drugset / Trial / NCT01332786
Safety Study Evaluating Intravenous Infusions of Tigecycline to Treat Acute Myeloid Leukemia
Phase 1
Completed
27 enrolled
University Health Network, Toronto
Memorial Sloan Kettering Cancer Center · collabUniversity of California, Los Angeles · collabUniversity of Kansas · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether tigecycline is safe and which dosage is most effective in the treatment of patients with acute myeloid leukemia.
Timeline
- Start
- 2011-03
- Primary completion
- 2014-10
- Completion
- 2015-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tigecycline | Small molecule | 50 mg | Intravenous |
| Subject | Tigecycline | Small molecule | 100 mg | Intravenous |
| Subject | Tigecycline | Small molecule | 150 mg | Intravenous |
| Subject | Tigecycline | Small molecule | 200 mg | Intravenous |
| Subject | Tigecycline | Small molecule | 250 mg | Intravenous |
| Subject | Tigecycline | Small molecule | 300 mg | Intravenous |
| Subject | Tigecycline | Small molecule | 350 mg | Intravenous |